ALIKO.PA Ikonisys SA

Healthcare Health Care Equipment & Supplies Euronext Paris
1.40 EUR
Close of Nov 4, 2026
1.30 1.84
Market cap
EUR 22.2M
P/E
-
P/B
1.21x
ROE
-22.0%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALIKO.PA undervalued?

Graham number

The Graham number of Ikonisys SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ikonisys SA fundamental analysis

3 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-13.3%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-237.17%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 2/2

With a remarkably low PBV ratio (0.75x), the stock offers substantial upside potential at a bargain price.

DER 2/2

The stock has a minimal amount of debt (14%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Net Profit Growth 0/2

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 1/1

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

Dividend Growth 0/2

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Dividend 0/2

The company's lack of dividends in the past three years may concern investors seeking regular income.

Buffet Intrinsic Value 0/1

The company's stock appears overvalued (-1) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Ikonisys SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ikonisys SA

Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that a…

Full company profile